Cookie Control

This site uses cookies to store information on your computer.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

By using our site you accept the terms of our Privacy Policy.

(One cookie will be set to store your preference)
(Ticking this sets a cookie to hide this popup if you then hit close. This will not store any personal information)

"He Fought Claims of Harm From Infant Formula. Now He Regulates It."

"Kyle Diamantas, a former corporate lawyer, is the new director for the F.D.A. food division, which oversees infant formula. He defended a top maker in cases claiming the company had not warned of potential risks to very low-weight babies."

"The new head of the Food and Drug Administration division that regulates infant formula was in recent months a corporate lawyer defending a top formula maker from claims that its product gave rise to debilitating harm to premature babies.

Kyle A. Diamantas joined the F.D.A. last month to lead the food division, leaving the law firm Jones Day, which has served as a pipeline of talent to both Trump administrations.

As a partner in Jones Day’s Miami office, Mr. Diamantas’s recent work included defending Abbott Laboratories in a lawsuit accusing the company of failing to adequately warn parents that its specialized formula for premature infants was associated with an elevated risk of a deadly bowel condition.

Abbott lost the case and was ordered to pay $495 million. Abbott is appealing the verdict. Mr. Diamantas’s role in that case and other Abbott cases has not been previously reported."

Christina Jewett reports for the New York Times March 4, 2025.

Source: NYTimes, 03/07/2025